Synthetic benzofuran-linked chalcones with dual actions: a potential therapeutic approach to manage diabetes mellitus

Future Med Chem. 2023 Jan;15(2):167-187. doi: 10.4155/fmc-2022-0247. Epub 2023 Feb 17.

Abstract

Background: Identification of molecules having dual capabilities to reduce postprandial hyperglycemia and oxidative stress is one of the therapeutic approaches to treat diabetes mellitus. In this connection, a library of benzofuran-linked chalcone derivatives were evaluated for their dual action. Methods: A series of substituted benzofuran-linked chalcones (2-33) were synthesized and tested for α-amylase inhibitory as well as 2,2-diphenylpicrylhydrazyl (DPPH) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical scavenging activities. Results: All compounds showed α-amylase inhibitory activity ranging from IC50 = 12.81 ± 0.03 to 87.17 ± 0.15 μM, compared with the standard acarbose (IC50 = 13.98 ± 0.03 μM). Compounds also demonstrated radical scavenging potential against DPPH and ABTS radicals. Conclusion: The identified compounds may serve as potential leads for further advanced research.

Keywords: benzofuran; chalcone; in silico; in vitro; radical scavenger; synthesis; α-amylase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzofurans* / pharmacology
  • Benzofurans* / therapeutic use
  • Chalcones* / chemistry
  • Chalcones* / pharmacology
  • Chalcones* / therapeutic use
  • Diabetes Mellitus* / drug therapy
  • Humans
  • alpha-Amylases

Substances

  • 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid
  • Chalcones
  • alpha-Amylases
  • Benzofurans